BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24022278)

  • 1. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.
    Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T
    Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
    Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
    J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
    J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.
    Su Y; Wang L; Zhao Q; Yue Z; Zhao W; Wang X; Duan C; Jin M; Zhang D; Chen S; Yin J; Qiu L; Cheng X; Xu Z; Ma X
    Mol Oncol; 2020 Nov; 14(11):2884-2893. PubMed ID: 32896084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.
    Iehara T; Hosoi H; Akazawa K; Matsumoto Y; Yamamoto K; Suita S; Tajiri T; Kusafuka T; Hiyama E; Kaneko M; Sasaki F; Sugimoto T; Sawada T
    Br J Cancer; 2006 May; 94(10):1510-5. PubMed ID: 16670717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction.
    Crabbe DC; Peters J; Seeger RC
    Diagn Mol Pathol; 1992 Dec; 1(4):229-34. PubMed ID: 1342970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
    Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R
    Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of MYCN amplification in neuroblastoma biopsies by differential polymerase chain reaction.
    Boerner S; Squire J; Thorner P; McKenna G; Zielenska M
    Pediatr Pathol; 1994; 14(5):823-32. PubMed ID: 7808981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients.
    Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A
    Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)].
    Pession A; De Bernardi B; Perri P; Mazzocco K; Rondelli R; Nigro M; Iolascon A; Forni M; Basso G; Conte M
    Pediatr Med Chir; 1994; 16(3):211-8. PubMed ID: 7971442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei.
    Valent A; BĂ©nard J; Clausse B; Barrois M; Valteau-Couanet D; Terrier-Lacombe MJ; Spengler B; Bernheim A
    Am J Pathol; 2001 May; 158(5):1579-84. PubMed ID: 11337354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-time quantitative PCR for the measurement of MYCN amplification in human neuroblastoma with the TaqMan detection system.
    Raggi CC; Bagnoni ML; Tonini GP; Maggi M; Vona G; Pinzani P; Mazzocco K; De Bernardi B; Pazzagli M; Orlando C
    Clin Chem; 1999 Nov; 45(11):1918-24. PubMed ID: 10545060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis.
    Zhang H; He X; Miao Q; Li L; Song J; Jiang X
    Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma.
    Hiyama E; Hiyama K; Yokoyama T; Fukuba I; Yamaoka H; Shay JW; Matsuura Y
    Clin Cancer Res; 1999 Mar; 5(3):601-9. PubMed ID: 10100712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.